- Home
- SPPL vs VTGN Comparison
SPPL vs VTGN Comparison
Compare SPPL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPPL | VTGN |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 21.8M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SPPL | VTGN |
|---|---|---|
| Price | $1.95 | $0.56 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 13.9K | ★ 422.3K |
| Earning Date | 04-08-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $0.43 |
| 52 Week High | $7.00 | $5.14 |
Technical Indicators
Market Signals| Indicator | SPPL | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 43.65 |
| Support Level | $1.50 | $0.50 |
| Resistance Level | $3.54 | $0.66 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 34.09 | 34.57 |
Price Performance
Historical ComparisonAbout SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.